公开(公告)号：US20180222982A1

公开(公告)日：2018-08-09

申请号：US15747873

申请日：2016-07-28

Applicant: Glenn Dranoff ,  Gordon James Freeman ,  Arlene Helen Sharpe ,  Walter A. Blattler ,  Jennifer Marie Mataraza ,  Catherine Anne Sabatos-Peyton ,  Hwai Wen Chang ,  Gerhard Johann Frey ,  Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Glenn Dranoff ,  Gordon James Freeman ,  Arlene Helen Sharpe ,  Walter A. Blattler ,  Jennifer Marie Mataraza ,  Catherine Anne Sabatos-Peyton ,  Hwai Wen Chang ,  Gerhard Johann Frey

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/395

CPC classification number: C07K16/2818 ,  A61K39/00 ,  A61K39/39541 ,  A61K2039/505 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

Abstract: Combination therapies comprising antibody molecules that specifically bind to PD-1 disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.

公开(公告)号：US20190000944A1

公开(公告)日：2019-01-03

申请号：US16065387

申请日：2016-12-21

Applicant: Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe ,  Novartis AG ,  The Trustees of the University of Pennsylvania ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Jennifer Brogdon ,  Hwai Wen Chang ,  Boris Engels ,  Gordon James Freeman ,  Gerhard Johann Frey ,  Jennifer Marie Mataraza ,  Reshma Singh ,  Arlene Helen Sharpe

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  A61K45/06

Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.

公开(公告)号：US20180207273A1

公开(公告)日：2018-07-26

申请号：US15747326

申请日：2016-07-28

Applicant: Glenn Dranoff ,  Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu ,  Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  Children's Medical Center Corporation

Inventor： Glenn Dranoff ,  Catherine Anne Sabatos-Peyton ,  Barbara Brannetti ,  Alan S. Harris ,  Thomas Huber ,  Thomas Pietzonka ,  Jennifer Marie Mataraza ,  Walter A. Blattler ,  Daniel J. Hicklin ,  Maximiliano Vasquez ,  Rosemarie H. DeKruyff ,  Dale T. Umetsu ,  Gordon James Freeman ,  Tiancen Hu ,  John A. Taraszka ,  Fangmin Xu

IPC: A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K39/39566 ,  A61K39/00 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/507 ,  A61P35/00 ,  C07K16/2803 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/94 ,  A61K2300/00

Abstract: Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.